Monday, September 10, 2018 1:17:47 AM
Couldn’t agree more. You will get nada in terms of answers to your questions. I hope I am wrong but I’ve been down that road multiple times.
At this point in Pro-140’s development the word from Gilead is you got nothing. They aren’t jumping at another Combo option regardless of Pro-140’s safety profile.
Mono would be a different story. Nader knows this and is ramping to the higher dosage to hopefully grab some serious attention with 80-90% Efficacy while maintaining a strong safety profile. The question here that everyone is asking is the same one I want answered (besides financing) where are we with the 700ml dosing? Are we moving or stagnant due to lack of $? Time is $ and at this pace it’s going to be years and a different market place in terms of competition.
When Tony C quietly disappeared with the addition of Pestell the company shifted to the Cancer story with Pestell to attract new investors. That was the only way to raise money with Paulson because the HIV well was dry. Will Pestell along with Klump change the financing picture and free us from Paulson? I’m hopefully optimistic.
Personally I don’t believe anything Nader has to say until it’s fact. Especially when it comes to financing.
At this point in Pro-140’s development the word from Gilead is you got nothing. They aren’t jumping at another Combo option regardless of Pro-140’s safety profile.
Mono would be a different story. Nader knows this and is ramping to the higher dosage to hopefully grab some serious attention with 80-90% Efficacy while maintaining a strong safety profile. The question here that everyone is asking is the same one I want answered (besides financing) where are we with the 700ml dosing? Are we moving or stagnant due to lack of $? Time is $ and at this pace it’s going to be years and a different market place in terms of competition.
When Tony C quietly disappeared with the addition of Pestell the company shifted to the Cancer story with Pestell to attract new investors. That was the only way to raise money with Paulson because the HIV well was dry. Will Pestell along with Klump change the financing picture and free us from Paulson? I’m hopefully optimistic.
Personally I don’t believe anything Nader has to say until it’s fact. Especially when it comes to financing.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
